|

Niraparib Clinical Trials

23 actively recruiting trials across 7 locations

▼ -2 trials since June 2026

Also known as: Arm A, Dostarlimab, GSK3985771, MK-4827, MK4827 +4 more

Pipeline

Phase 1: 1Phase 2: 15Phase 3: 3Phase 4: 1Phase 1/2: 2Phase 2/3: 1

Top Sponsors

  • M.D. Anderson Cancer Center2
  • ARCAGY/ GINECO GROUP2
  • Wigen Biomedicine Technology (Shanghai) Co., Ltd.1
  • University of Miami1
  • University of California, San Francisco1

Indications

  • Cancer23
  • Ovarian Cancer5
  • Fallopian Tube Cancer3
  • Neoplasia2
  • Tumors2

Other15 trials

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
Phase 1/2
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
Phase 1/2
Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer
Phase 2
Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC
Phase 2
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Phase 2
Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
Phase 2
Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab
Phase 2
Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma
Phase 2
Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer
Phase 2
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
Phase 3
Personalized Medicine for Advanced Biliary Cancer Patients
Phase 3
ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
Phase 2
Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
Phase 2/3
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
Phase 2
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2

Houston, Texas2 trials

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

M D Anderson Cancer Center

Phase 2
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

M D Anderson Cancer Center

Phase 2

Tucson, Arizona1 trial

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

GSK Investigational Site

Phase 2

San Francisco, California1 trial

Combination Therapy in Cancers With Mutations in DNA Repair Genes

University of California, San Francisco

Phase 1

Fort Lauderdale, Florida1 trial

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

Broward Health

Phase 4

Orlando, Florida1 trial

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Advent Health

Phase 3

Tampa, Florida1 trial

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Moffitt Cancer Center

Phase 2

Boston, Massachusetts1 trial

Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

Dana-Farber Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.